Key result
Single-pill combinations linked to ~13% lower risk of death and hospitalizations versus multi-pill regimens.
Why the study?
Current guidelines recommend single pill combinations to improve adherence in hypertension and cardiovascular prevention, but clinical superiority over multi pill combinations with identical drugs is unclear.
Does single pill combination therapy improve clinical outcomes compared to identical multi pill therapy in patients with hypertension and/or cardiovascular disorders?
Cohort (n=59,336)
Does single pill combination therapy improve clinical outcomes compared to identical multi pill therapy in patients with hypertension and/or cardiovascular disorders?
Single pill combinations of cardiovascular drugs are associated with lower all-cause mortality and hospitalizations compared to identical multi-pill regimens in real-world clinical practice.
Answers are grounded in this paper and cite their sources.
May support single-pill combinations in hypertension; hypothesis-generating and should not change practice without randomized confirmation.
AIM: Current guidelines for the treatment of arterial hypertension (AH) or cardiovascular (CV) prevention recommend combination drug treatments with single pill combinations (SPC) to improve adherence to treatment. We aimed to assess whether the SPC concept is clinically superior to multi pill combination (MPC) with identical drugs. METHODS AND RESULTS: In an explorative study, we analyzed anonymized claims data sets of patients treated with CV drugs for hypertension and/or CV disorders who were insured by the German AOK PLUS statutory health fund covering 01/07/2012-30/06/2018. Patients at age ≥18 years who received either a SPC or MPC with identical drugs were followed for up to one year. A one to one propensity score matching (PSM) was applied within patient groups who started identical drug combinations, and results were reported as incidence rate ratios (IRRs) as well as hazard ratios (HRs). After PSM, data from 59,336 patients were analyzed. In 30 out of 56 IRR analyses, superiority of SPC over MPC was shown. In 5 out of 7 comparisons, the HR for the composite outcome of all-cause death and all-cause hospitalizations was in favor of the SPC regimen (SPC versus MPC): valsartan/amlodipine: HR=0.87 (95% CI: 0.84-0.91, p ≤ 0.001); candesartan/amlodipine: 0.77 (95% CI: 0.65-0.90, p = 0.001); valsartan/amlodipine/hydrochlorothiazide: HR=0.68 (95% CI: 0.61-0.74, p ≤ 0.001); ramipril/amlodipine: HR=0.80 (95% CI: 0.77-0.83, p ≤ 0.001); acetylsalicylic acid (ASA)/atorvastatin/ramipril: HR=0.64 (95% CI: 0.47-0.88, p = 0.005). CONCLUSION: SPC regimens are associated with a lower incidence of CV events and lower all-cause mortality in clinical practice. SPC regimens should generally be preferred to improve patient's prognosis.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Hypertension and/or cardiovascular disorders (n=59,336). Single pill combinations (SPC) vs. Multi pill combination (MPC) with identical drugs was evaluated on Composite outcome of all-cause death and all-cause hospitalizations (HR 0.87, 95% CI 0.84-0.91, p=≤0.001). Single pill combinations were associated with a lower risk of all-cause death and hospitalizations compared to identical multi pill combinations.
Synapse has enriched 10 related papers. Consider them for comparative context: